Immuno-Oncology | Specialty

Dr. Bauml Discusses Immunotherapy Agents in Head and Neck Cancer

August 3rd 2017

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses immunotherapy agents in head and neck cancer.

Dr. Atkins on Sequencing of Immunotherapy Combination Regimens

August 3rd 2017

Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of oncology and medicine, Georgetown University School of Medicine, discusses sequencing of immunotherapy combination regimens for patients with renal cell carcinoma (RCC).

Pembrolizumab Plus Epacadostat Active in RCC

August 2nd 2017

Primo N. Lara Jr, MD, discusses the KEYNOTE-037 pembrolizumab/epacadostat findings in patients with advanced RCC, and how the combination could change treatment in this population.

Dr. Balar on PD-L1 Testing for Urothelial Cancer

August 2nd 2017

Arjun V. Balar, MD, assistant professor of medicine, Division of Hematology and Oncology, Perlmutter Cancer Center, NYU Langone Medical Center, discusses PD-L1 testing and the development of biomarkers for PD-L1 antibodies for patients with urothelial carcinoma.

Dr. Nowakowski on the Potential Role of Immunotherapy in MCL

August 1st 2017

Grzegorz S. Nowakowski, MD, assistant professor of medicine at Mayo Clinic, discusses what potential immunotherapy agents have in the treatment landscape of mantle cell lymphoma (MCL).

FDA Approves Nivolumab for MSI-H or dMMR Colorectal Cancer

August 1st 2017

The FDA has granted an accelerated approval to nivolumab for the treatment of adult and pediatric patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.

Future Focus on Combinations, Biomarkers in Metastatic NSCLC

August 1st 2017

The therapeutic paradigm continues to evolve in advanced non-small cell lung cancer, with increased emphasis being placed on rational combinations and biomarkers in the next few years.

New Strategy Boosts Microenvironment to Promote Antitumor Immunity in GI Metastases

August 1st 2017

Despite the promise of immunotherapy for treating patients with advanced cancers, the success of using such therapies for progressive gastrointestinal malignancies such as colorectal liver metastases (CRLM) has been limited so far.

Prostate Cancer: Advice for Oncologists on AR-V7 Testing

July 31st 2017

Experimental Strategies for AR-V7+ CRPC

July 31st 2017

Precision Medicine in mCRPC

July 31st 2017

Recent AR-V7 Data in Prostate Cancer

July 31st 2017

Prostate Cancer: Educating Physicians About AR-V7 Testing

July 31st 2017

Practical Implications of AR-V7 Testing in Prostate

July 31st 2017

Prostate Cancer: Validation of AR-V7 Testing

July 31st 2017

John's Hopkins AR-V7 Test in Prostate

July 31st 2017

Prostate Cancer: Epic Sciences AR-V7 Test

July 31st 2017

Detection of AR-V7 in Prostate Cancer

July 31st 2017

AR-V7 as a Predictive Marker in Prostate Cancer

July 31st 2017

Prostate Cancer: Discovery and Importance of AR-V7

July 31st 2017